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Abstract 
Accumulating evidence suggests that inflammation may play a role in the 
pathophysiology of major depressive disorder (MDD). Antidepressants, including 
selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine 
reuptake inhibitors (SNRIs), possess anti-inflammatory effects in vitro. Here, we 
examined the effects of SSRIs and SNRIs on lipopolysaccharide (LPS)-induced 
inflammation and depressive-like behavior in male mice. A single administration of LPS 
(0.5 mg/kg, i.p.) increased serum levels of the pro-inflammatory cytokine, tumor 
necrosis factor alpha (TNF) and the anti-inflammatory cytokine, interleukin-10 
(IL-10) in mice. Pretreatment with SSRIs (fluoxetine and paroxetine), SNRIs 
(venlafaxine and duloxetine), or 5-hydroxytryptophan (5-HTP), a precursor of serotonin, 
attenuated LPS-induced increases in TNF, whereas it increased serum levels of IL-10, 
in mice treated with LPS. In the tail suspension test (TST), LPS increased the 
immobility time without affecting spontaneous locomotor activity, suggesting that LPS 
induced depressive-like behavior in mice. Treatment with fluoxetine (30 mg/kg) or 
paroxetine (10 mg/kg) significantly shortened LPS-induced increases of immobility 
time. These results suggested that antidepressants exert anti-inflammatory effects in vivo, 
and that the serotonergic system may partially mediate these effects. In addition, the 
anti-inflammatory effects of antidepressants may help alleviate the symptoms of 
LPS-induced depression in mice. 
 2
Abbreviation list 
MDD, Major depressive disorder; TNF, Tumor necrosis factor alpha; IL, Interleukin; 
NSAIDs, Non-steroidal anti-inflammatory drugs; MADRS, Montgomery-Asberg 
Depression Rating Scale; RA, Rheumatoid arthritis; LPS, Lipopolysaccharide; FST, 
Forced swimming test; TST, Tail suspension test; SSRI, Selective serotonin reuptake 
inhibitor; SNRI, Serotonin and norepinephrine uptake inhibitor; IFN, Interferon; 5-HTP, 
5-Hydroxy-tryptophan; ELISA, Enzyme Immunosorbent Assay; i.p., Intraperitoneally; 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; ANOVA, Analysis of variance; 
SERT, Serotonin transporter; IDO, Indoleamine-2, 3-dioxigenase. 
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1. Introduction 
Major depressive disorder (MDD) is a common and recurrent mood disorder. The 
estimated lifetime prevalence is approximately 16.6% (Kessler et al., 2003). However, 
little is known about the pathophysiology of MDD (Hashimoto, 2009; Hashimoto et al., 
2004). Accumulating evidence suggests that inflammation may play a role in the 
pathophysiology of MDD. Meta-analysis shows higher blood levels of 
pro-inflammatory cytokines, such as tumor necrosis factor  (TNF) and interleukin-6 
(IL-6), in drug-free depressive patients compared with healthy controls (Dowlati et al., 
2010). A postmortem brain study showed elevated gene expression of pro-inflammatory 
cytokines in frontal cortex of people with a history of MDD (Shelton et al., 2011). A 
non-steroidal anti-inflammatory drug (NSAID) celecoxib was capable of augmenting 
the therapeutic efficacy of the selective serotonin reuptake inhibitor (SSRI) sertraline in 
MDD (Abbasi et al., 2012). Therapeutic administration of interferon- (IFN) in 
patients with hepatitis-C, increases pro-inflammatory cytokine levels in serum, leading 
to depressive symptoms. This increase of pro-inflammatory cytokines correlates 
positively with the severity of depression as indicated by the Montgomery-Asberg 
Depression Rating Scale (MADRS) (Bonaccorso et al., 2001; Wichers et al., 2007). 
Moreover, rheumatoid arthritis (RA) and the accompanying systemic inflammation 
shows high comorbidity with depression, and therapeutic administration of anti-TNF 
antibodies reduces this high prevalence of depression (Uguz et al., 2009). These 
findings suggest that both peripheral and central inflammations are associated with 
depressive symptoms, and that inhibition of the inflammatory process could ameliorate 
these symptoms. 
In animal studies, peripheral administration of bacterial endotoxin 
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lipopolysaccharide (LPS) (Kang et al., 2011; O'Connor et al., 2009) or TNF (Kaster et 
al., 2012) induces depressive-like behavior in the forced swimming test (FST) and the 
tail suspension test (TST). LPS-induced depressive-like behavior is blocked by NSAIDs, 
while TNF-induced depressive-like behavior is blocked by anti-TNF antibodies (de 
Paiva et al., 2010; Kaster et al., 2012), suggesting a link between inflammation and 
depressive symptoms. SSRIs and serotonin and norepinephrine reuptake inhibitors 
(SNRIs) have been widely used as antidepressant drugs. In vitro assays show some 
antidepressants also possess anti-inflammatory properties, in central- and 
peripheral-derived cells (Diamond et al., 2006; Horikawa et al., 2010; Liu et al., 2011). 
For example, SSRIs, such as paroxetine and sertraline, inhibit interferon- 
(IFN-induced TNF and nitric oxide (NO) elevation in a murine microglial cell line 
(Horikawa et al., 2010). Venlafaxine shows anti-inflammatory effects through the 
suppression of IFN/IL-10 production ratio (Kubera et al., 2001). A meta-analysis 
shows that SSRI treatment decreases TNF levels in human serum (Hannestad et al., 
2011a), and alleviates depressive symptoms (Tuglu et al., 2003). Therefore, it is likely 
that the anti-inflammatory effects of antidepressants might contribute to their 
therapeutic efficacy in MDD patients. 
In this study, we examined the effects of two types of antidepressants (SSRI: 
fluoxetine, paroxetine, SNRI: venlafaxine, duloxetine) on LPS-induced inflammation, 
as measured by changes in the pro-inflammatory cytokine TNF and anti-inflammatory 
cytokine interleukin-10 (IL-10) levels in mice. Furthermore, we evaluated the effects of 
fluoxetine and paroxetine on LPS-induced depressive-behavior in the TST. 
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2. Materials and methods 
2.1. Animals 
Male BALB/c mice were purchased from Japan SLC., Shizuoka, Japan and were 
used for all experiments at 8 weeks of age. Mice were housed in a room maintained at 
23 ± 2 °C with a 12/12 hour light/dark cycle (lights on at 7:00 AM), and with free 
access to food and water. All animal care and use were in accordance with the 
Institutional Guidelines for Animal Care and Use (Otsuka Pharmaceutical Co., Ltd., 
Tokushima, Japan). 
2.2. Drugs 
Fluoxetine hydrochloride was synthesized at Otsuka Pharmaceutical Co., Ltd. 
Paroxetine hydrochloride (GlaxoSmithKlein plc., Brentford, UK), venlafaxine 
hydrochloride (Pfizer, Inc., New York, NY, USA), and duloxetine hydrochloride (Eli 
Lilly and Co., Indianapolis, USA) were purchased from the companies as stated. 
5-Hydroxytryptophan (5-HTP) and LPS from Escherichia Coli (0127:B8) were obtained 
from Sigma-Aldrich Co. LLC. (St Louis, MO, USA). 
2.3. Drug treatment and Enzyme-Linked Immunosorbent Assay (ELISA) 
Vehicle (10 ml/kg, physiological saline injected intraperitoneally [i.p.]), 
fluoxetine, paroxetine, venlafaxine, or duloxetine (3, 10, or 30 mg/kg) were 
administered to mice. Vehicle (20 ml/kg, physiological saline injected i.p.) or 5-HTP (30, 
100, or 300 mg/kg) were administered to mice. The stated doses of antidepressants were 
referred to the effective dose in behavioral tests (FST or TST) (Berrocoso et al., 2004; 
El Yacoubi et al., 2003; Redrobe et al., 1998a; Redrobe et al., 1998b; Wang et al., 2008; 
Wong et al., 2000). The dose range for 5-HTP was enough to induce a behavioral 
change (head-twitch) in a previous study, and was thus used here (Krisch and 
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Bole-Vunduk, 1994). Thirty minutes after drug administration, LPS (0.5 mg/kg, i.p.) 
was injected into mice. Blood samples were taken via a cardiac puncture, under 
isoflurane anesthesia (Mylan Inc., Tokyo, Japan), 90 minutes after LPS injection. Blood 
was coagulated and centrifuged at 2,000 g, for 20 minutes to generate serum samples. 
This experimental condition was referred to the report (Sugino et al., 2009). Serum 
samples were diluted with ELISA diluent solution (eBioscience Inc., San Diego, CA, 
USA) 20-fold to measure TNF and 10-fold for IL-10. TNF and IL-10 serum 
concentrations were measured using a Ready-SET-Go ELISA kit (eBioscience), 
according to manufacturer’s instructions. 
2.4. Spontaneous locomotor activity measurement 
Thirty minutes after vehicle (10 ml/kg, physiological saline, i.p.), fluoxetine (30 
mg/kg) or paroxetine (10 mg/kg) administration, mice were injected with vehicle (10 
ml/kg, physiological saline, i.p.) or LPS (0.5 mg/kg). Twenty-four hours later, mice 
were placed in a novel cage, the same size as their home cage (14.3 cm × 35.3 cm), 
without bedding, and allowed to explore freely. Spontaneous locomotion was measured 
for 6 minutes using a passive infrared ray sensor in the Supermex system (Muromachi 
Kikai Co., Ltd., Tokyo, Japan). After measurements, blood samples were collected 
under isoflurane anesthesia for ELISA. After cervical dislocation, whole brain was 
taken and cut coronally at optic chiasm. Prefrontal cortex was obtained by carefully 
removing olfactory bulb, septum and striatum from anterior brain region and then used 
for real-time PCR analysis. 
2.5. Tail suspension test 
Thirty minutes after vehicle (10 ml/kg, physiological saline, i.p.), fluoxetine (30 
mg/kg) or paroxetine (10 mg/kg) administration, mice were injected with vehicle (10 
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ml/kg, physiological saline, i.p.) or LPS (0.5 mg/kg). Twenty-four hours later, mice 
were suspended upside down by their tails. The immobility time was automatically 
measured for 6 minutes, using an analyzing system (Yamashita Giken, Tokushima, 
Japan). The experiment was carried out in a soundproof room. 
2.6. Quantitative real-time RT-PCR 
Total RNA from prefrontal cortex was extracted using the RNeasy Lipid Tissue 
Mini Kit (QIAGEN Inc., Valencia, CA, USA). RNA was reverse transcribed to cDNA 
using the SuperScript VILO cDNA Synthesis Kit (Invitrogen co., Carlsbad, CA, USA). 
Real-time reverse transcription PCR was performed using the Applied Biosystems 7500 
Fast Real-Time PCR System. TaqMan Gene Expression Assays (Applied Biosystems 
Co., Foster City, USA) for TNF (Mm00443258_m1) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Mm99999915_g1), and TaqMan Fast Universal PCR Master 
Mix (Applied Biosystems Co.) were used for reaction mixtures, with 50 ng of cDNA 
template. GAPDH was used as the endogenous house keeping control gene. 
2.7. Statistical analysis  
ELISA data were expressed as a percentage of the LPS-treated group. Data were 
presented as the mean ± standard error of the mean (S.E.M.). Statistical analyses were 
performed using one-way analysis of variance (ANOVA), followed post hoc Dunnett 
test for ELISA or two-way ANOVA, followed post hoc Bonferroni test for behavioral 
evaluations and real-time PCR analysis, on Prism 5 (GraphPad Software Inc., La Jolla, 
USA). P values less than 0.05 was considered statistically significant. 
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3. Result 
3.1. Effects of antidepressants on serum cytokine levels 
In order to examine inflammation in vivo, we injected LPS (0.5 mg/kg), a 
component of the outer membrane of gram-negative bacteria, into mice. Ninety minutes 
after injection, blood was collected and serum levels of the pro-inflammatory cytokine 
TNF and the anti-inflammatory cytokine IL-10 were determined. In saline-treated 
mice, TNF and IL-10 levels were under our detection limits. Serum levels of TNF 
and IL-10 increased after a single administration of LPS (Table 1).  
 
Table.1. Effects of LPS on serum cytokine levels of mice 
 
 TNF 
(pg/mL) 
IL-10 
(pg/mL) 
Saline 
LPS 
N.D. 
4142 ± 650 
N.D. 
481 ± 63 
  Data are expressed as the mean ± SEM. (n = 7), N.D.: Not Detected. 
 
We examined the effects of SSRIs (fluoxetine and paroxetine) and SNRIs 
(venlafaxine and duloxetine) on serum levels of TNF and IL-10, in mice treated with 
LPS (0.5 mg/kg). Mice were pretreated with the drug 30 minutes prior to LPS injection, 
and blood was collected 90 minutes after LPS injection. Pretreatment with fluoxetine (3, 
10, or 30 mg/kg) or paroxetine (3, 10, or 30 mg/kg) significantly attenuated 
LPS-induced TNF increases, in a dose-dependent manner (fluoxetine; F (3, 22) = 
15.34, P < 0.01, paroxetine; F (3, 23) = 20.31, P < 0.01) (Figure 1A and 1C). Both 
fluoxetine (3, 10, or 30 mg/kg) and paroxetine (10, or 30 mg/kg) significantly increased 
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serum levels of IL-10 in mice treated with LPS also in a dose dependent manner 
(fluoxetine; F (3, 23) = 37.68, P < 0.01, paroxetine; F (3, 24) = 41.66, P < 0.01) (Figure 
1B and 1D).  
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Figure.1. Effects of fluoxetine and paroxetine on LPS-induced cytokine increase in 
serum. Thirty minutes after a single i.p. administration of vehicle (10 ml/kg), fluoxetine 
(3, 10, or 30 mg/kg) or paroxetine (3, 10, or 30 mg/kg), LPS (0.5 mg/kg, i.p.) was 
injected. Blood sample was collected 90 minutes after LPS injection. Serum 
concentration of TNF and IL-10 was measured with ELISA. (A) Fluoxetine, TNF. 
(B) Fluoxetine, IL-10. (C) Paroxetine, TNF (D) Paroxetine, IL-10. Data are expressed 
as percentage of vehicle + LPS treated group, and data were shown the mean ± SEM (n 
= 6-7). *P < 0.05, **P < 0.01 compared with vehicle + LPS treated group.  
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Similarly, venlafaxine (10, or 30 mg/kg) and duloxetine (3, 10, or 30 mg/kg) 
significantly attenuated LPS-induced TNF increases (venlafaxine; F (3, 22) = 3.811, P 
< 0.05, duloxetine; F (3, 23) = 9.445, P < 0.01) (Figure 2A and 2C). Venlafaxine (3, 10, 
or 30 mg/kg) and duloxetine (10, or 30 mg/kg) significantly increased serum levels of 
IL-10 in mice treated with LPS, in a dose-dependent manner (venlafaxine; F (3, 23) = 
15.93, P < 0.01, duloxetine; F (3, 24) = 50.45, P < 0.01) (Figure 2B and 2D).  
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Figure.2. Effects of venlafaxine and duloxetine on LPS-induced cytokine increase 
in serum. Thirty minutes after a single i.p. administration of vehicle (10 ml/kg), 
venlafaxine (3, 10, or 30 mg/kg) or duloxetine (3, 10, or 30 mg/kg), LPS (0.5 mg/kg, 
i.p.) was injected. Blood sample was collected 90 minutes after LPS injection. 
Concentration of TNF and IL-10 was measured with ELISA. (A) Venlafaxine, TNF. 
(B) Venlafaxine, IL-10. (C) Duloxetine, TNF. (D) Duloxetine, IL-10. Data are 
expressed as percentage of vehicle + LPS treated group, and data were shown the mean 
± SEM (n = 6-7). *P < 0.05, **P < 0.01 compared with vehicle + LPS treated group. 
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To determine whether the serotonergic system makes an essential contribution 
to the anti-inflammatory effects of antidepressants, we pretreated LPS-challenged mice 
with 5-HTP, a precursor of serotonin. Pretreatment with 5-HTP (30, 100, or 300 mg/kg) 
significantly attenuated LPS-induced increases in TNF, in a dose dependent manner (F 
(3, 24) = 62.05, P < 0.01) (Figure 3A). Furthermore, pretreatment with 5-HTP also 
increased serum levels of IL-10 in mice treated with LPS, in a dose-dependent manner 
(F (3, 24) = 40.17, P < 0.01). Two doses (100 or 300 mg/kg) of 5-HTP were statistically 
significant (Figure 3B). 
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Figure.3. Effects of 5-HTP on LPS-induced cytokine increase in serum. Thirty 
minutes after a single i.p. administration of vehicle (20 ml/kg) or 5-HTP (30, 100, or 
300 mg/kg), LPS (0.5 mg/kg, i.p.) was injected. Blood sample was collected 90 minutes 
after LPS injection. Concentration of TNF and IL-10 was measured with ELISA. (A) 
5-HTP, TNF. (B) 5-HTP, IL-10. Data are expressed as percentage of vehicle + LPS 
treated group, and data were shown the mean ± SEM (n = 5-7). **P < 0.01 compared 
with vehicle + LPS treated group. 
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3.2. Behavioral evaluations 
We performed behavioral evaluations using the spontaneous locomotor activity 
tests and TST 24 hours after LPS (0.5 mg/kg) injection. This time course was selected 
because LPS could induce depressive-like behavior in mice 24 hours after LPS injection 
(O'Connor et al., 2009). Mice were pretreated with fluoxetine (30 mg/kg), 30 minutes 
prior to LPS injection. Spontaneous locomotor activity did not differ between saline- 
and LPS-treated mice, and fluoxetine (30 mg/kg) pretreatment had no effects on 
spontaneous locomotor activity in saline- and LPS-treated mice (LPS, F (1, 26) = 2.296, 
P = 0.1418; fluoxetine, F (1, 26) = 0.8042, P = 0.3781; interaction, F (1, 26) = 3.873, P 
= 0.0598) (Figure 4A). Next we examined anti-inflammatory effects of fluoxetine on 
LPS-induced behavioral changes in the TST. The immobility time of LPS-treated mice 
was significantly higher than that of saline-treated mice (P < 0.05). Fluoxetine (30 
mg/kg) significantly shortened immobility time, both in saline- (P < 0.01) and 
LPS-treated mice (P < 0.01) (LPS, F (1, 43) = 13.02, P < 0.01; fluoxetine, F (1, 43) = 
29.08, P < 0.01; interaction, F (1, 43) = 0.5137, P = 0.477) (Figure 4B). 
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Figure.4. Antidepressant-like effect of fluoxetine on LPS-treated mice. Thirty 
minutes after a single i.p. administration of vehicle (10 ml/kg) or fluoxetine (30 mg/kg), 
saline (10 ml/kg) or LPS (0.5 mg/kg, i.p.) was injected. Behavioral tests were performed 
24 hr following saline or LPS injection. (A) Spontaneous locomotor activity was 
measured for 6 minutes. (B) The duration of immobility time in TST was measured for 
6 minutes. Data are shown the mean ± SEM (n = 6-12). *P < 0.05, **P < 0.01 compared 
with vehicle + saline treated group. ##P < 0.01 compared with vehicle + LPS treated 
group. 
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Next, we examined effects of paroxetine in behavioral tests. LPS (0.5 mg/kg, 24 
hrs) didn’t affect spontaneous locomotor activity. Paroxetine (10 mg/kg) had no effect 
on spontaneous locomotor activity in saline- and LPS-treated mice (LPS, F (1, 28) = 
0.0466, P = 0.8306; paroxetine, F (1, 28) = 0.3442, P = 0.5621; interaction, F (1, 28) = 
0.8267, P = 0.371) (Figure 5A). In the TST, LPS induced depressive-like behavior (P < 
0.01), and pretreatment with paroxetine (10 mg/kg) significantly attenuated the increase 
of immobility time in LPS-treated mice (P < 0.01), without affecting saline-treated mice 
(LPS, F (1, 43) = 2.854, P = 0.0984; paroxetine, F (1, 43) = 8.24, P < 0.01; interaction, F 
(1,43) = 13.9, P < 0.01) (Figure 5B). 
Next, we collected blood and brain (prefrontal cortex) samples immediately after 
measuring spontaneous locomotor activity. At this time point, serum levels of TNF and 
IL-10 were under detectable limits (data not shown). Levels of TNF mRNA in the 
prefrontal cortex of LPS-treated mice were significantly higher than levels in 
saline-treated mice (P < 0.01). Pretreatment with paroxetine (10 mg/kg) significantly (P 
< 0.01) attenuated increases in TNF mRNA induced by LPS (LPS, F (1, 28) = 22.39, P 
< 0.01; paroxetine, F (1, 28) = 11.52, P < 0.01; interaction, F (1, 28) = 6.489, P < 0.05) 
(Figure 5C). In contrast, IL-10 mRNA levels in the prefrontal cortex were undetectable 
(data not shown).  
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Figure.5. Antidepressant-like effect of paroxetine on LPS-treated mice. Thirty 
minutes after a single i.p. administration of vehicle (10 ml/kg) or paroxetine (10 mg/kg), 
saline (10 ml/kg) or LPS (0.5 mg/kg, i.p.) was injected. Behavioral tests were performed 
24 hr following saline or LPS injection. (A) Spontaneous locomotor activity was 
measured for 6 minutes. (B) The duration of immobility time in TST was measured for 
6 minutes. (C) Immediately after measurement of spontaneous locomotion, prefrontal 
cortex was collected and real-time PCR was performed for TNF mRNA analysis. Data 
were shown the mean ± SEM (n = 8-12). **P < 0.01 compared with vehicle + saline 
treated group. ##P < 0.01 compared with vehicle + LPS treated group. 
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4. Discussion 
This study showed that antidepressants such as SSRIs and SNRIs possess 
anti-inflammatory action in the periphery, as measured by decreased TNF levels and 
up-regulated IL-10 levels in LPS-treated mice. In the TST, we demonstrated that 
LPS-treated mice displayed depressive-like behavior 24 hours after LPS injection, and 
that fluoxetine and paroxetine showed antidepressant-like effects in this model. 
It has been reported that SSRIs and SNRIs possess anti-inflammatory effects in 
vitro (Horikawa et al., 2010; Kubera et al., 2001). This study suggests that serotonin 
uptake inhibition may be an important process in the anti-inflammatory action of these 
drugs. Both SSRIs and SNRIs exert their therapeutic effect by inhibiting the serotonin 
transporter (SERT) in the brain, thereby increasing extracellular serotonin 
concentrations. In the periphery, SERT is expressed in platelets and regulates plasma 
serotonin levels (Mercado and Kilic, 2010). SSRIs inhibit peripheral SERT while 
sharply increasing plasma serotonin levels (Ortiz and Artigas, 1992). Serotonin receptor 
subtypes 4 and 7 are expressed in monocytes and their stimulation decreases LPS 
induced TNF release (Durk et al., 2005). Furthermore, 5-HTP, which is converted to 
serotonin by the aromatic L-amino acid decarboxylase, also decreased TNF levels in 
LPS-treated mice, suggesting that serotoninergic activation may be essential for 
anti-inflammatory action. Taken together, it is likely that the inhibitory effects of SSRIs 
and SNRIs on LPS-induced TNF increases are the result of serotonin receptor 
stimulation. This activation is mediated through increases in plasma serotonin levels 
induced by SERT inhibition in the peripheral system. 
IL-10 is one of the most essential anti-inflammatory cytokines. It acts by 
inhibiting the production of pro-inflammatory cytokines such as TNF and IL-6 (de 
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Waal Malefyt et al., 1991). The inhibitory effects of TNF production stimulated by 
acute administration of SSRIs and SNRIs would in part be due to the upregulation of 
IL-10, in addition to serotonin receptor stimulation, although the precise mechanisms 
for this up-regulation by these antidepressants remain unknown. In this study, we found 
that 5-HTP increased serum levels of IL-10 in mice. Therefore, it seems that serotonin 
plays an important role in IL-10 upregulation induced by SSRIs and SNRIs. 
IL-10 is a key regulator of depression symptoms (Roque et al., 2009). IL-10 
knockout mice show depressive-like behavior compared with wild-type mice, and this 
behavior is reversed by IL-10 administration. Conversely, mice overexpressing IL-10 
display antidepressant-like behavior compared with wild-type mice (Mesquita et al., 
2008). Furthermore, IL-10 suppresses the HPA axis, thereby inhibiting the secretion of 
corticosterones by the adrenal gland (Roque et al., 2009). From these reports, it is likely 
that IL-10 up-regulation induced by SSRIs and SNRIs contributes to the therapeutic 
effect seen in MDD. 
In the TST, LPS-treated mice showed prolonged immobility time, with no change 
in spontaneous locomotor activity, compared with saline-treated mice. This finding is in 
agreement with previous reports (Kang et al., 2011; O'Connor et al., 2009). The report 
states that locomotor activity in mice decreases transiently 6 hours after LPS injection 
and recovers at around 24 hours after injection. This short term decrease in locomotor 
activity after LPS injections is called sickness-behavior, and is due to acute 
inflammation. Sickness behavior is distinguishable from depressive behavior and can be 
monitored by recording spontaneous locomotor activity (Frenois et al., 2007). In this 
study, behavioral changes were observed 24 hours after LPS challenge and there were 
no differences in spontaneous locomotor activity between saline- and LPS-treated mice. 
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From this, we conclude that our LPS-treated mice showed depressive-like behavior in 
this study. We found that serum levels of TNF and IL-10 were undetectable 24 hours 
after LPS challenge, suggesting that within the periphery, LPS-induced increases of 
these cytokines had tapered off within this timeframe. Interestingly, we found that, 24 
hours after LPS injection, TNF mRNA levels in the brain were significantly higher 
than those of saline-treated mice. It has been proposed that peripheral inflammation may 
relay signals to the central nervous system (Krishnadas and Cavanagh, 2012). Peripheral 
LPS injections induced depressive-like behaviors through the pro-inflammatory 
cytokine-induced, indoleamine-2, 3-dioxigenase (IDO) enzyme (O'Connor et al., 2009), 
and SERT activation in the brain (Zhu et al., 2010). Therefore, peripheral and central 
inflammation would be involved in depressive-like behavior in mice treated with LPS. 
Fluoxetine and its active metabolite, norfluoxetine occupy mouse brain SERT, 24 
hours after fluoxetine administration (Hirano et al., 2004). Taking this into consideration, 
it is not surprising that fluoxetine shortened immobility time at 24 hours, in 
saline-treated mice. Fluoxetine also shortened immobility time in LPS-treated mice, 
suggesting that fluoxetine was effective in treating LPS-induced depressive-like 
behavior. On the other hand, paroxetine disappeared from mouse brains 24 hours after 
administration (Hirano et al., 2004). At this time point, paroxetine showed no 
antidepressant-like effect in saline-treated mice (Figure 5B). However, paroxetine 
attenuated LPS-induced depressive-like behavior. Furthermore, paroxetine pretreatment 
inhibited LPS-induced TNF mRNA increases in prefrontal cortex. It is likely that 
paroxetine attenuated LPS-induced increases in TNF in the periphery and in doing so, 
inhibited inflammation in the brain and following depressive-like behavior. In addition, 
paroxetine inhibits IFN- induced microglial activation (Horikawa et al., 2010), 
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suggesting that paroxetine may inhibit LPS-induced TNF mRNA increases in the brain, 
by inhibiting microglial activation. It has been reported that inhibiting inflammatory 
processes in the periphery ameliorated depressive-like behavior induced by peripheral 
LPS challenge (Kang et al., 2011). Therefore, inhibition of inflammatory processes in 
the periphery may be enough to prevent inflammation-induced depressive-like behavior. 
Recently, Arakawa et al. (2012) reported that minocycline, a potent inhibitor of 
microglial activation, produced antidepressant-like effects on the learned helplessness 
rats, an animal model of depression. These results suggest that the anti-inflammatory 
properties of antidepressants confer an antidepressant-like effect on 
inflammation-induced depressive-like behavior.  
Clinical studies have shown that IFNinduces depressive symptoms in hepatitis 
C patients, and that this symptom onset can be prevented by pretreatment with SSRIs 
(McNutt et al., 2012; Schaefer et al., 2012). Citalopram reduces endotoxin-induced 
fatigue in human (Hannestad et al., 2011b). Our findings on fluoxetine and paroxetine in 
the treatment of LPS-induced depressive-like behavior lend support to these clinical 
studies (McNutt et al., 2012; Schaefer et al., 2012). MDD patients have higher levels of 
pro-inflammatory cytokines in their blood (Dowlati et al., 2010), and inflammation in 
frontal cortex was observed in people with a history of MDD (Shelton et al., 2011). 
SSRIs decrease TNF levels in MDD patients (Hannestad et al., 2011a) and the 
decrease is associated with therapeutic effect (Tuglu et al., 2003). From these evidences, 
inflammation in the periphery and brain might be involved in the pathophysiology of 
depressive symptoms in human. Therefore, SSRIs and SNRIs may in part ameliorate 
depressive symptoms, by inhibiting peripheral and central inflammation through their 
known anti-inflammatory effects. 
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In conclusion, these findings suggest that antidepressants such as SSRIs and 
SNRIs possess anti-inflammatory effects. They are capable of decreasing LPS-induced 
TNF increases and up-regulating IL-10 levels in serum. It is these anti-inflammatory 
effects which inhibit the depressive-like behavior seen in LPS-treated mice. Therefore, 
the anti-inflammatory effects of SSRIs and SNRIs may partially contribute to their 
therapeutic effect in MDD.  
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